التفاصيل البيبلوغرافية
| العنوان: |
Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis. |
| المؤلفون: |
Boyne, Devon J., Dawe, David E., Shakir, Huma, Joe-Uzuegbu, Ofodile, Farah, Eliya, Pabani, Aliyah, Baratta, Cristina, Brenner, Darren R., Cheung, Winson Y. |
| المصدر: |
Targeted Oncology; Sep2023, Vol. 18 Issue 5, p697-705, 9p |
| مستخلص: |
Background: Based on findings from a single-arm, phase 2 basket trial (NCT02454972), lurbinectedin may be an effective treatment for individuals with small cell lung cancer (SCLC) who progressed on or after platinum-based chemotherapy. Objective: To estimate the comparative effectiveness of lurbinectedin versus the historical standard of care for relapsed SCLC in Canada. Methods: A synthetic control arm (SCA) analysis was conducted using real-world data. Population-level data were obtained from real-world databases in Alberta, Canada. Individuals diagnosed with SCLC who initiated post-platinum systemic therapy and met approximated eligibility criteria from the lurbinectedin trial were included in the SCA. Median overall survival (OS) in the SCA was estimated after adjusting for chemotherapy-free interval (CTFI; < 90 versus ≥ 90 days) and stage at initial diagnosis (extensive versus limited). The CTFI-adjusted hazard ratio was estimated using a Cox proportional hazards model. Results: One hundred seventy-four individuals were included in the SCA and 105 in the lurbinectedin trial. The adjusted median OS in the SCA was 6.1 months (95% CI 5.4–7.7 months; unadjusted: 6.7 months, 95% CI 6.0–7.7 months) versus 9.3 months (95% CI 6.3–11.8 months) in the lurbinectedin trial. The adjusted hazard ratio comparing lurbinectedin with the historical standard of care (referent group) was 0.61 (95% CI 0.45–0.82; unadjusted HR: 0.72; 95% CI 0.54–0.97). The hazard ratio was more pronounced among individuals with CTFI ≥ 90 days (HR: 0.49, 95% CI 0.33–0.73). Conclusion: These findings suggest improved OS with lurbinectedin monotherapy versus the historical standard of care in Alberta, Canada. [ABSTRACT FROM AUTHOR] |
|
Copyright of Targeted Oncology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
